Eli Lilly candidate shows weight loss at 11 percent in phase III trial
![Photo: Mike Blake/REUTERS / X00030](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article12617771.ece/ALTERNATES/schema-16_9/doc7djyvfzf6r51j521cda1.jpg)
US pharmaceutical firm Eli Lilly have oresented the initial results for the phase III study for the company's drug candidate tirzepatide against obesity.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Nordisk submits obesity drug for FDA approval
For subscribers
New CEO gets rid of a number of Ambu executives
For subscribers